Highlights from the Q2 2009 review of pharmaceutical and biotechnology dealmaking: In biopharma financing, the FOPO had a comeback bringing in $773 million with 11 transactions--a deal volume the public markets haven't achieved since Q1 2008. Cephalon and Dendreon led the pack, each with follow-on offerings exceeding the $100 million mark. There weren't the mega Big Pharma mergers done in previous months, however, there was a clear interest in generics as witnessed by Sanofi-Aventis' buyouts of two generics firms, and Watson and Novartis also getting in on the action, each through $1 billion+ acquisitions in this arena as well. As far as alliances were concerned, the top spot belongs to GlobeImmune, which granted Celgene exclusive worldwide rights to its {Targomen} cancer programs (including two clinical-stage candidates) in exchange for a potential $540 million pay day.Q2 also saw many companies shifting therapeutic focus to in-license products and candidates new to them in order to revive pipelines and beef up portfolios.
In this issue, we present another installment of our quarterly
review of pharmaceutical/biotechnology dealmaking—for the
second quarter of 2009. Our data come from Elsevier's Strategic
Transactions.
Amanda Micklus and Maureen Riordan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
